前列腺素E2在癌症发生发展中的研究进展

被引:23
作者
蒋彩虹 [1 ,2 ]
高子蕊 [1 ]
郭丽凯 [1 ]
章琳琪 [1 ]
范天睿 [1 ]
王月丹 [1 ]
初明 [1 ]
机构
[1] 北京大学医学部基础医学院
[2] 新疆石河子大学食品学院
基金
北京市自然科学基金;
关键词
前列腺素E2; 癌症;
D O I
暂无
中图分类号
R730.2 [肿瘤病理学、病因学];
学科分类号
100214 [肿瘤学];
摘要
环氧合酶2、微粒体前列腺素E合酶1催化产生的前列腺素E2在肿瘤的发展过程中具有重要作用。COX2/PEG2途径的失调通过多种机制影响癌症的发生和发展。如促进肿瘤细胞的增殖和存活、抗凋亡,在肿瘤微环境中,前列腺素E2的升高促进血管再生、肿瘤细胞的粘附和迁移,促进癌症的转移。因此,研发在前列腺素E2合成过程中关键酶的抑制剂是治疗前列腺素E2相关癌症的策略之一。
引用
收藏
页码:53 / 57
页数:5
相关论文
共 8 条
[1]
Prostaglandin E2 receptor 4 mediates renal cell carcinoma intravasation and metastasis.[J].Yushan Zhang;Hamsa Thayele Purayil;Joseph B. Black;Francis Fetto;Lauren D. Lynch;Jude N. Masannat;Yehia Daaka.Cancer Letters.2017,
[2]
Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice [J].
Wang, Dingzhi ;
Fu, Lingchen ;
Sun, Haiyan ;
Guo, Lixia ;
DuBois, Raymond N. .
GASTROENTEROLOGY, 2015, 149 (07) :1884-+
[3]
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity [J].
Zelenay, Santiago ;
van der Veen, Annemarthe G. ;
Boettcher, Jan P. ;
Snelgrove, Kathryn J. ;
Rogers, Neil ;
Acton, Sophie E. ;
Chakravarty, Probir ;
Girotti, Maria Romina ;
Marais, Richard ;
Quezada, Sergio A. ;
Sahai, Erik ;
Reis e Sousa, Caetano .
CELL, 2015, 162 (06) :1257-1270
[4]
Identification and development of mPGES-1 inhibitors: where we are at? [J].
Chang, Hui-Hua ;
Meuillet, Emmanuelle J. .
FUTURE MEDICINAL CHEMISTRY, 2011, 3 (15) :1909-1934
[5]
Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology [J].
Harizi, Hed ;
Corcuff, Jean-Benoit ;
Gualde, Norbert .
TRENDS IN MOLECULAR MEDICINE, 2008, 14 (10) :461-469
[6]
Connecting COX-2 and Wnt in cancer [J].
Buchanan, FG ;
DuBois, RN .
CANCER CELL, 2006, 9 (01) :6-8
[7]
COX-2 inhibits fas-mediated apoptosis in cholangiocarcinoma cells [J].
Nzeako, UC ;
Guicciardi, ME ;
Yoon, JH ;
Bronk, SF ;
Gores, GY .
HEPATOLOGY, 2002, 35 (03) :552-559
[8]
ALTERATIONS IN CELLULAR ADHESION AND APOPTOSIS IN EPITHELIAL-CELLS OVEREXPRESSING PROSTAGLANDIN-ENDOPEROXIDE-SYNTHASE-2 [J].
TSUJII, M ;
DUBOIS, RN .
CELL, 1995, 83 (03) :493-501